SCHEMBL6846514

SCHEMBL6846514

CC(C)(C)OC(=O)N1CCN(c2cccc(NC(=O)c3cccc(CCc4ccc(N)nc4)c3)c2C(F)(F)F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.41
HDAC1 Q13547 3/20 0.40
MAPK8 P45983 1/20 0.40
PTPN11 Q06124 1/20 0.40
LIPG Q9Y5X9 1/20 0.40
MET P08581 1/20 0.39
BACE1 P56817 3/20 0.39
RXFP1 Q9HBX9 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SCD O00767 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6841382 0.90 WNT3A (0.41) TSHRHSD17B10ALDH1A1GAAATM
SCHEMBL6846512 0.88 PTPN11 (0.40) TSHRALDH1A1GAAPTPN11LIPG
SCHEMBL6844797 0.85 MET (0.39) TSHRHSD17B10ALDH1A1GAAATM
SCHEMBL6848356 0.85 ALDH1A1 (0.43) TSHRHSD17B10ALDH1A1GAAATM
SCHEMBL6846441 0.80 TSHR (0.47) TSHRHSD17B10ALDH1A1ATMMAPK8
SCHEMBL7546596 0.80 HDAC1 (0.40) HDAC1
SCHEMBL6841380 0.78 TRPV1 (0.41) METBACE1SCDSCD5ACHE
SCHEMBL6846841 0.77 HTT (0.37) TSHRHSD17B10ALDH1A1ATMHDAC1
SCHEMBL6846606 0.76 BACE1 (0.44) TSHRHSD17B10ALDH1A1MAPK8BACE1
SCHEMBL6844737 0.75 TOP1 (0.42) TSHRHSD17B10MAPK8BACE1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA TSHR 2259/4885HSD17B10 3952/4885ALDH1A1 3632/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA TSHR 2259/4885HSD17B10 3952/4885ALDH1A1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.